NEW YORK (GenomeWeb) – Liquid biopsy firm CellMax Life said today that it has received an NT$23 million ($760,846) grant from the Taiwan Government Industrial Development Bureau Ministry of Economic Affairs. 

The company plans to use the funding to accelerate its efforts to automate its circulating tumor cell-based technology, and to advance plans for world-wide commercialization of its early cancer detection platform CMxTM.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.